Evidence map›Paper›PMID 37681524›Full record

ArticleJournal of the American Heart Association2023

Decoding Angiotensin Receptors: TOMAHAQ-Based Detection and Quantification of Angiotensin Type-1 and Type-2 Receptors.

Caglar Cosarderelioglu, Simion Kreimer, Alma I Plaza-Rodriguez, Pablo A Iglesias, C Conover Talbot, Helmy M Siragy, Robert M Carey, Ceereena Ubaida-Mohien, Brian O'Rourke, Luigi Ferrucci and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  3. Review
  4. Enhanced Sample Multiplexing-Based Targeted Proteomics with Intelligent Data Acquisition.Journal of the American Society for Mass Spectrometry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Caglar CosardereliogluDivision of Geriatric Medicine and Gerontology Johns Hopkins University School of Medicine Baltimore MD.ORCID 0000-0002-7560-1287
Simion KreimerThe Mass Spectrometry and Proteomics Facility Johns Hopkins University School of Medicine Baltimore MD.ORCID 0000-0001-6627-3771
Alma I Plaza-RodriguezKrieger School of Arts and Sciences Johns Hopkins University Baltimore MD.
Pablo A IglesiasDepartment of Electrical and Computer Engineering, Whiting School of Engineering Johns Hopkins University Baltimore MD.ORCID 0000-0002-0840-155X
C Conover TalbotInstitute for Basic Biomedical Sciences, Johns Hopkins University School of Medicine Baltimore MD.ORCID 0000-0002-3758-2425
Helmy M SiragyDivision of Endocrinology and Metabolism, Department of Medicine University of Virginia Charlottesville VA.
Robert M CareyDivision of Endocrinology and Metabolism, Department of Medicine University of Virginia Charlottesville VA.ORCID 0000-0001-7238-7396
Ceereena Ubaida-MohienNational Institute on Aging, National Institutes of Health Baltimore MD.ORCID 0000-0002-4301-4758
Brian O'RourkeDivision of Cardiology, Department of Medicine Johns Hopkins University Baltimore MD.ORCID 0000-0002-5548-4853
Luigi FerrucciNational Institute on Aging, National Institutes of Health Baltimore MD.ORCID 0000-0002-6273-1613
David A BennettRush Alzheimer's Disease Center Rush University Medical Center Chicago IL.ORCID 0000-0003-3689-554X
Jeremy WalstonDivision of Geriatric Medicine and Gerontology Johns Hopkins University School of Medicine Baltimore MD.
Peter AbadirDivision of Geriatric Medicine and Gerontology Johns Hopkins University School of Medicine Baltimore MD.ORCID 0000-0002-8186-0066
Johns Hopkins University · USNational Institutes of Health · USUniversity of Virginia · USRush University Medical Center · US

Funding

Technological Assessment and Solutions Core - RC4P30AG021334 · NIA · JOHNS HOPKINS UNIVERSITY · PI Jeremy D Walston · 2003 to 2026
$33.2M
Age Related Change in Mitochondrial Angiotensin System and Mitochondrial DeclineR01AG046441 · NIA · JOHNS HOPKINS UNIVERSITY · PI ABADIR, PETER M. · 2014 to 2018
$2.3M
AGE RELATED CHANGE IN ANGIOTENSIN RECEPTORS AND ITS ROLE IN CHRONIC INFLAMMATIONK23AG035005 · NIA · JOHNS HOPKINS UNIVERSITY · PI ABADIR, PETER M. · 2010 to 2014
$807k
NIA NIH HHS K23 AG035005NIA NIH HHS P30 AG021334NIA NIH HHS R01 AG046441
6 · The paper itself

Abstract

Background The renin-angiotensin system plays a crucial role in human physiology, and its main hormone, angiotensin, activates 2 G-protein-coupled receptors, the angiotensin type-1 and type-2 receptors, in almost every organ. However, controversy exists about the location, distribution, and expression levels of these receptors. Concerns have been raised over the low sensitivity, low specificity, and large variability between lots of commercially available antibodies for angiotensin type-1 and type-2 receptors, which makes it difficult to reconciliate results of different studies. Here, we describe the first non-antibody-based sensitive and specific targeted quantitative mass spectrometry assay for angiotensin receptors. Methods and Results Using a technique that allows targeted analysis of multiple peptides across multiple samples in a single mass spectrometry analysis, known as TOMAHAQ (triggered by offset, multiplexed, accurate mass, high resolution, and absolute quantification), we have identified and validated specific human tryptic peptides that permit identification and quantification of angiotensin type-1 and type-2 receptors in biological samples. Several peptide sequences are conserved in rodents, making these mass spectrometry assays amenable to both preclinical and clinical studies. We have used this method to quantify angiotensin type-1 and type-2 receptors in postmortem frontal cortex samples of older adults (n=28) with Alzheimer dementia. We correlated levels of angiotensin receptors to biomarkers classically linked to renin-angiotensin system activation, including oxidative stress, inflammation, amyloid-β load, and paired helical filament-tau tangle burden. Conclusions These robust high-throughput assays will not only catalyze novel mechanistic studies in the angiotensin research field but may also help to identify patients with an unbalanced angiotensin receptor distribution who would benefit from angiotensin receptor blocker treatment.

Indexed as

AngiotensinsReceptors, AngiotensinAgedAngiotensin Receptor AntagonistsAntibodiesHumansRenin-Angiotensin SystemAngiotensin Receptor AntagonistsAngiotensinsAntibodiesReceptors, Angiotensinaccurate massand absolute quantification)angiotensinangiotensin type‐1 receptorangiotensin type‐2 receptorbrainhigh resolutionmultiplexedTOMAHAQ (triggered by offset

Identifiers

PMID37681524
PMCPMC10547273
OpenAlexW4386529464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.